Open AccessReducedTrypanosoma cruzi-specific humoral response and enhanced T cell immunity after treatment interruption with benznidazole in chronic Chagas disease
Author(s) -
Melisa D. Castro Eiro,
María A. Natale,
M Alvarez,
Huifeng Shen,
Rodolfo Viotti,
Bruno Lococo,
Jacqueline Búa,
Myriam Núñez,
Graciela Bertocchi,
María Cecilia Albareda,
Gonzalo César,
Rick L. Tarleton,
Susana A. Laucella
Publication year - 2021
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkab054
Subject(s) - benznidazole , chagas disease , trypanosoma cruzi , immunology , regimen , medicine , antibody , cd8 , cellular immunity , immune system , parasite hosting , world wide web , computer science
Interruption of benznidazole therapy due to the appearance of adverse effects, which is presumed to lead to treatment failure, is a major drawback in the treatment of chronic Chagas disease.